Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes

Stroke

Volumn 37, Issue 7, 2006, Pages 1910-1912

  Wang, Sophia ^a,c   Lee, Sun Ryung ^a,b   Guo, Shu Zhen ^a   Kim, Woo Jean ^a   Montaner, Joan ^d   Wang, Xiaoying ^a   Lo, Eng H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Jeju National University   (South Korea)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hemorrhage; Stroke

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALTEPLASE; GELATINASE B; RHO KINASE; RHO KINASE INHIBITOR; SIMVASTATIN; AMIDE; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROPROTECTIVE AGENT; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN CORTEX; CONTROLLED STUDY; ENZYME ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; ZYMOGRAPHY; ANIMAL; BIOSYNTHESIS; BRAIN HEMORRHAGE; CELL CULTURE; CEREBROVASCULAR ACCIDENT; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME INDUCTION; ENZYMOLOGY; GENETICS;

AMIDES; ANIMALS; ASTROCYTES; CELLS, CULTURED; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEUROPROTECTIVE AGENTS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RATS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 33745950917     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000226923.48905.39     Document Type: Article

References (15)

1. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001;21:7724-7732.
2. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32:1759-1766.
3. Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke. 2004;35:354-356.
4. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-1317.
5. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
6. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836.
7. Wang X, Mori T, Sumii T, Lo EH. Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. Stroke. 2002;33:1882-1888.
8. Menge T, Hartung HP, Stuve O. Statins-a cure-all for the brain? Nat Rev Neurosci. 2005;6:325-331.
9. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
10. Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T, Qiu J, Amin-Hanjani S, Huang PL, Liao JK, Lo EH, Moskowitz MA. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:722-729.
11. Kilic E, Kilic U, Matter CM, Luscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor but does not depend on endothelial no synthase. Stroke. 2005;36:332-336.
12. Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, Hozeska A, Zhang C, Li L, Morris D, Zhang RL, Lu M, Chopp M. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation. 2005;112:3486-3494.
13. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285-288.
14. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunties in stroke. Nat Rev Neurosci. 2003;4:399-415.
15. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, Liao JK. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005;36:2251-2257.